Emulate Stock
Organs-on-Chips Company
About Emulate Stock
Emulate, Inc. is a private company focused on commercializing Organs-on-Chips as an automated human bioemulation platform that achieves a new standard for mimicking true human physiology so that responses to medicines, chemicals and diseases can be accurately predicted. Through co-innovation with collaborators and internal programs, Emulate is advancing product innovation, design and safety across a range of applications in drug development, personalized medicine, agriculture and chemical-based consumer products.
Investors
ALS Investment Fund
ATEL Ventures
Glass Wall Syndicate
NanoDimension
National Institutes of Health
OS Fund
Human Longevity, Emulate, Elysium Health, uBiome, 3T Biosciences
Techammer
Funding History
| July 2014 | $12.0M |
|---|---|
| March 2016 | $28.0M |
| October 2016 | $17.0M |
| June 2017 | $2.0M |
| June 2018 | $36.0M |
Management
Co-Founder & Chief Science Officer
Geraldine A. Hamilton
Chief Executive Officer
Martin Madaus
Chief Technology Officer
Daniel Levner
Press
Bandera County Courier - Mar, 9 2020
Bio IT World - Nov, 21 2019
Outsourcing Pharma - Jun, 28 2018
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Emulate or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
